Compare Merck & Co., Inc. (MRK) vs J M Smucker Co (SJM) Price & Performance

Merck & Co., Inc.Trade

J M Smucker CoTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs J M Smucker Co — how do they compare? Merck & Co., Inc. trades at $126.14 (market cap $307.25B), while J M Smucker Co trades at $112.69 (market cap $11.97B). The key difference: Merck & Co., Inc. is far larger — about 25.7× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.93%). Which is the better fit depends on your goals.

	MRK	SJM
Market Cap	$307.25B	$11.97B
Sector	Health	Consumer Staples
52-Week High	$129.52	$117.05
52-Week Low	$77.60	$89.53
Enterprise Value	$350.66B	$19.00B
Dividend Yield	2.73%	3.93%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.

Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.

J M Smucker Co

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 5 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 2 days agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

SJM

Affiliated Managers Group and Madison Square Garden shares rise on strong quarterly resultsSeeking Alpha · 1 day agoBullish J.M. Smucker raises quarterly dividend by 2% to $1.12, marking 25 years of consecutive growth.PRNewsWire · 4 days agoBullish View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About J M Smucker Co

J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.